Close Menu

Natera: Rowan Chapman

Rowan Chapman has joined the board of directors of Natera. Most recently, she was head of Johnson & Johnson Innovation for Western North America, Australia, and New Zealand; head of precision diagnostics at GE Healthcare Life Sciences; and managing director of new business creation and head of healthcare investing at GE Ventures. Prior to that, she was a partner at Mohr Davidow Ventures. Chapman holds a BA in biochemistry and a PhD in biochemistry and molecular biology from the University of Cambridge.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

The New York Times reports on how environmental DNA sampling could monitor endangered species.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.